Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results
Journal
The World Allergy Organization journal
Journal Volume
13
Journal Issue
9
Date Issued
2020-09
Author(s)
Abstract
A Worldwide Antihistamine-Refractory Chronic Urticaria (CU) patient Evaluation (AWARE) is a non-interventional, multicenter study including patients from Europe, Central and Latin America, Asia-Pacific, and the Middle East. AWARE describes real-world evidence for CU, including clinical characteristics, treatment patterns and the impact on quality of life.
Subjects
AMAC, Asia-Pacific and the Middle East; AWARE, A Worldwide Antihistamine-Refractory Chronic Urticaria patient Evaluation; Angioedema; CIndU, chronic inducible urticaria; CSU, chronic spontaneous urticaria; CU, chronic urticaria; DLQI, dermatology life quality index; Dermatology; LaCAN, Central and Latin America; PRO, patient-reported outcome; QoL, quality of life; Quality-of-life; SD, standard deviation; UAS7, 7-day urticaria activity score; Urticaria
Other Subjects
cyclosporine; histamine H1 receptor antagonist; montelukast; omalizumab; 7 day urticaria activity score; adult; angioneurotic edema; Article; chronic inducible urticaria; chronic urticaria; Dermatology Life Quality Index; drug use; female; human; major clinical study; male; patient-reported outcome; priority journal; quality of life; skin disease assessment
Type
journal article